We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors

By MedImaging International staff writers
Posted on 05 Jan 2024
Print article
Image: A research team has drawn up criteria for PET-based examinations of malignant brain tumors (Photo courtesy of 123RF)
Image: A research team has drawn up criteria for PET-based examinations of malignant brain tumors (Photo courtesy of 123RF)

Diffuse gliomas, which are aggressive malignant brain tumors originating from glial cells, present significant treatment challenges. Standard magnetic resonance imaging (MRI) techniques do not adequately capture the complexity of diffuse gliomas. Instead, amino acid positron emission tomography (PET) has become a crucial tool in diagnosing these tumors. This method utilizes protein-based tracers (amino acids) that accumulate in brain tumors, offering more accurate insights into the activity and extent of gliomas. Despite its extensive use in neuro-oncology for years, amino acid PET had not undergone systematic evaluation, and unlike MRI diagnostics, there have been no established criteria for interpreting these PET images.

Now, the international Response Assessment in Neuro-Oncology (RANO) Working Group, guided by experts from Ludwig Maximilian University of Munich (LMU, Munich, Germany) and the Medical University of Vienna (Vienna, Austria), has introduced the first-ever global standards for gliomas imaging using amino acid PET. The RANO Working Group, a diverse international consortium with a decade-long history of developing criteria to serve as standard references for brain tumor-related clinical studies, has made significant strides in assessing various critical clinical aspects.

The RANO group has formulated PET RANO 1.0, a set of criteria aimed at evaluating the effectiveness of treatments for diffuse gliomas using PET. These PET-based standards usher in novel avenues for the uniform assessment of diffuse gliomas. The researchers believe that these new criteria not only facilitate the use of PET in clinical trials and routine practice but also lay a solid groundwork for future investigations, fostering the comparison and enhancement of treatment modalities for better therapeutic outcomes.

Related Links:
LMU
Medical University of Vienna

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Digital Radiography System
meX+20BT
New
Radiation Therapy Treatment Software Application
Elekta ONE
New
1.5T Superconducting MRI System
uMR 680

Print article
Radcal

Channels

Radiography

view channel
Image: 3D cinematic renderings of the control and diseased heart in anatomic orientation (Photo courtesy of ESRF)

Innovative X-Ray Technique Captures Human Heart with Unprecedented Detail

Cardiovascular disease remains the leading cause of death globally. In 2019, ischemic heart disease, which weakens the heart due to reduced blood supply, accounted for approximately 8.9 million or 16%... Read more

MRI

view channel
Image: SubtleSYNTH creates synthetic STIR images with zero acquisition time that are interchangeable with conventionally acquired STIR images (Photo courtesy of Subtle Medical)

AI-Powered Synthetic Imaging Software to Further Redefine Speed and Quality of Accelerated MRI

The development of innovative solutions is not only redefining the landscape of artificial intelligence (AI)-based diagnostic imaging but also simplifying the ever-increasing complexity of workflows faced... Read more

Ultrasound

view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

General/Advanced Imaging

view channel
Image: HeartFlow Plaque Analysis leverages cutting-edge AI for assessment of plaque quantity and composition (Photo courtesy of HeartFlow, Inc.)

Next Gen Interactive Plaque Analysis Platform Assesses Patient Risk in Suspected Coronary Artery Disease

A first-of-its-kind plaque analysis tool to be fully integrated with FFRCT (when FFRCT is performed) provides impactful insights that enhance clinical decision-making and enable personalized patient treatment... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.